金吾财讯 | 再鼎医药(ZLAB)盘前涨超3%，截至发稿，报30.11美元。消息面上，再鼎医药公布第一季度财报，按美国公认会计准则，总收入1.06亿美元，按年增加22.2%。亏损净额由上年同期5,347万美元，收窄至4,844万美元，主要是产品收入的增长快于运营开支；每股亏损4美仙。公司重申，2025年全年收入指引介乎5.6亿至5.9亿美元。总裁兼首席营运官Josh Smiley表示，公司正稳步迈向于今年第四季实现非公认会计准则下扭亏为盈的目标，又指2025年是公司的蜕变之年，目前正在全力推进年初制定的各项关键目标，展望未来预料贝玛妥珠单抗和KarXT等后期管线产品，将与核心产品卫伟迦一同推动财报增长。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.